A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
City of Hope Medical Center
BeiGene
Kura Oncology, Inc.
Northwestern University
University of Nebraska
University of Nebraska
Mayo Clinic
National Institutes of Health Clinical Center (CC)
Masonic Cancer Center, University of Minnesota
Fred Hutchinson Cancer Center
Mayo Clinic
Roswell Park Cancer Institute
University of Chicago
Barbara Ann Karmanos Cancer Institute
Case Comprehensive Cancer Center
Wake Forest University Health Sciences
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
University of Washington
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Alliance for Clinical Trials in Oncology
Mayo Clinic
Columbia University
National Cancer Institute (NCI)
University of South Florida
Northside Hospital, Inc.
Northside Hospital, Inc.